top of page
Browse by category
Search


Combination of the Allurion Program with low-dose GLP-1 therapy to optimise muscle mass and GLP-1 adherence
Allurion Technologies has announced initial results on the combination of the Allurion Program with low-dose GLP-1 therapy to optimise...

Why women experience stronger side effects from GLP-1s
There are fundamental sex-based differences in how weight loss medications interact with human biology, according to a study by Olio...


SOS: Partial weight recurrence after substantial weight loss increases vascular disease
Partial weight recurrence after substantial weight loss was associated with a less favourable cardiovascular risk profile and an...


Biolexis reveals allosteric activation mechanism for the GLP-1 receptor
Biolexis Therapeutics has achieved a transformative milestone in metabolic drug discovery with the successful resolution of the...


Chchd10 protein's regulation of adipose tissue suggests new obesity management strategies
Researchers from the Department of Pharmacology and Pharmacy, LKS Faculty of Medicine at the University of Hong Kong (HKUMed), identified...


Expert consensus: AI poised to revolutionise the future of BMS ethical considerations must be addressed
An international consensus panel of 68 leading bariatric and metabolic surgery (BMS) from 35 countries has concluded that there are...
Browse by tag





bottom of page